CTX GPW sWIG80 Periodic report · PAP Biznes
Captor Therapeutics SA (CTX) · Q2 2026 results
Share price: 52.40 zł · 2026-11-10
Results Q2 2026 vs Q2 2025 · year over year · published 15 Sep 2026 and 12 Sep 2025
The language turned more cautious.
Only a basic analysis is available for this company at the moment.
1 · Numbers
—
No financial figures for this pair
2 · How the report reads
More cautious
Language tone vs last period
Report language: restrained for a company report — more cautious than in Q2 2025.
Weak signal: formal report language, not a call.
3 · What stood out
Captor Therapeutics SA reported a net loss of PLN 22.8 million in the first half of 2026, which was slightly higher than the loss incurred the previous year.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
52.40 zł
close of 2026-11-10
Revenue growth, 3 years
−20.2% a year
compound annual rate (CAGR)
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q2 2025.
Restrained for a company report — more cautious than in Q2 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.
Sentences that drove the tone
“intermediary intending to make legal and organizational changes that may have a negative impact on the implementation”
“The net loss in the first half of 2026 amounted to PLN 22.8 million and was slightly higher than the loss incurred the previous year.”
Full figures
PLN · PAP Biznes report (2026-09-15)
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | 2.0M | — | |
| Gross profit | 1.8M | — | |
| Operating income | -24.2M | — | |
| Net income | -22.8M | — | |
| EPS | -3.86 | — | |
| P/E | 12-mo loss | — | — |
Topics
Topics are drawn from the full report text, not management commentary.
Most discussed now
- Fading In the report for the first half of 2025, proceeds from the issuance of Series T shares were presented in cash flows from operating…
- New The group's funds were invested in: treasury bonds, debt fund units, bank deposits.
- New Description Amount resulting from Potential liability Type of promissory note conditional agreements
- New These expenditures include: − costs of materials and services used or consumed in the production of an intangible asset
- New The parent company issues blank promissory notes for each grant agreement (for each project).
Faded since Q2 2025
- Fading Captor Therapeutics is responsible for formulating the opinion on this condensed interim financial statement based on the review it has…
Latest announcements
Official filings, newest first.
- Podpisanie umowy o dofinansowanie z The Michael J. Fox Foundation w ramach projektu NEK7 · ESPI 39/2026
- Half-year report · ESPI periodic
- Zakończenie subskrypcji akcji serii Z emitowanych w związku z realizacją programu motywacyjnego dla pracowników Spółki · ESPI 38/2026
- Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR · ESPI 37/2026
- Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR · ESPI 36/2026
- Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR · ESPI 35/2026
- Wykaz akcjonariuszy posiadających na Zwyczajnym Walnym Zgromadzeniu Spółki 19 czerwca 2026 r. co najmniej 5% głosów · ESPI 34/2026
- Powołanie Rady Nadzorczej Spółki kolejnej kadencji · ESPI 33/2026